Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15

Rhea-AI Summary

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology firm focused on treating serious diseases, will have its CEO, Jonathan Violin, participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022, at 10:40 a.m. ET. This event highlights the company's efforts to advance new therapies, particularly VRDN-001, a monoclonal antibody for thyroid eye disease, and VRDN-002, a half-life extended treatment option. Interested parties can view the live webcast and replay on Viridian's website.

WALTHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in a fireside chat at the 32^nd Annual Oppenheimer Healthcare Conference on March 15, 2022.

32nd Annual Oppenheimer Healthcare Conference
Format:		Fireside Chat
Date:		Tuesday, March 15, 2022
Time:		10:40 a.m. ET
Webcast Link

The live webcast and a replay of the fireside chat can be accessed under “Events” in the Investors section of the Viridian Therapeutics, Inc. website.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). Viridian’s second product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low-volume, subcutaneous injection. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.

Investor and Media Contact:
John Jordan
Viridian Therapeutics
Vice President, Investor Relations
& Corporate Communications
617-272-4691
IR@viridiantherapeutics.com

 

FAQ

What is the date and time of the fireside chat for Viridian Therapeutics?

The fireside chat will take place on March 15, 2022, at 10:40 a.m. ET.

Who is participating in the 32nd Annual Oppenheimer Healthcare Conference for VRDN?

Jonathan Violin, Ph.D., President and CEO of Viridian Therapeutics, will participate.

Where can I watch the Viridian Therapeutics fireside chat?

The fireside chat can be accessed via a live webcast available on Viridian's official website.

What is the focus of Viridian's product candidate VRDN-001?

VRDN-001 is a monoclonal antibody targeting insulin-like growth factor-1 receptor for treating thyroid eye disease.

What distinguishes VRDN-002 from VRDN-001?

VRDN-002 is an anti-IGF-1R antibody designed for convenient, low-volume, subcutaneous injection.